Endocannabinoid System Biomarkers in Alzheimer's Disease
(2023) In Cannabis and Cannabinoid Research 8(1). p.77-91- Abstract
Background: Alterations in the endocannabinoid system (ES) have been described in Alzheimer's disease (AD) pathophysiology. In the past years, multiple ES biomarkers have been developed, promising to advance our understanding of ES changes in AD. Discussion: ES biomarkers, including positron emission tomography with cannabinoid receptors tracers and biofluid-based endocannabinoids, are associated with AD disease progression and pathological features. Conclusion: Although not specific enough for AD diagnosis, ES biomarkers hold promise for prognosis, drug-target engagement, and a better understanding of the disease. Here, we summarize currently available ES biomarker findings and discuss their potential applications in the AD research... (More)
Background: Alterations in the endocannabinoid system (ES) have been described in Alzheimer's disease (AD) pathophysiology. In the past years, multiple ES biomarkers have been developed, promising to advance our understanding of ES changes in AD. Discussion: ES biomarkers, including positron emission tomography with cannabinoid receptors tracers and biofluid-based endocannabinoids, are associated with AD disease progression and pathological features. Conclusion: Although not specific enough for AD diagnosis, ES biomarkers hold promise for prognosis, drug-target engagement, and a better understanding of the disease. Here, we summarize currently available ES biomarker findings and discuss their potential applications in the AD research field.
(Less)
- author
- organization
- publishing date
- 2023
- type
- Contribution to journal
- publication status
- published
- subject
- keywords
- Alzheimer's disease, biomarkers, dementia, endocannabinoid
- in
- Cannabis and Cannabinoid Research
- volume
- 8
- issue
- 1
- pages
- 15 pages
- publisher
- Mary Ann Liebert, Inc.
- external identifiers
-
- pmid:36394442
- scopus:85148737104
- ISSN
- 2378-8763
- DOI
- 10.1089/can.2022.0151
- language
- English
- LU publication?
- yes
- id
- 7c95b1e3-6897-4008-ae82-951cfc650b65
- date added to LUP
- 2023-03-16 10:32:32
- date last changed
- 2025-02-07 10:41:04
@article{7c95b1e3-6897-4008-ae82-951cfc650b65, abstract = {{<p>Background: Alterations in the endocannabinoid system (ES) have been described in Alzheimer's disease (AD) pathophysiology. In the past years, multiple ES biomarkers have been developed, promising to advance our understanding of ES changes in AD. Discussion: ES biomarkers, including positron emission tomography with cannabinoid receptors tracers and biofluid-based endocannabinoids, are associated with AD disease progression and pathological features. Conclusion: Although not specific enough for AD diagnosis, ES biomarkers hold promise for prognosis, drug-target engagement, and a better understanding of the disease. Here, we summarize currently available ES biomarker findings and discuss their potential applications in the AD research field.</p>}}, author = {{Ferreira, Pâmela C.L. and Bellaver, Bruna and Povala, Guilherme and Brum, Wagner S. and Tissot, Cécile and Badji, Atef and Sloan, Matthew E. and Benedet, Andréa L. and Rosa-Neto, Pedro and Ashton, Nicholas J. and Pascoal, Tharick A. and Leuzy, Antoine and Zimmer, Eduardo R.}}, issn = {{2378-8763}}, keywords = {{Alzheimer's disease; biomarkers; dementia; endocannabinoid}}, language = {{eng}}, number = {{1}}, pages = {{77--91}}, publisher = {{Mary Ann Liebert, Inc.}}, series = {{Cannabis and Cannabinoid Research}}, title = {{Endocannabinoid System Biomarkers in Alzheimer's Disease}}, url = {{http://dx.doi.org/10.1089/can.2022.0151}}, doi = {{10.1089/can.2022.0151}}, volume = {{8}}, year = {{2023}}, }